Infant Phototherapy Device Market size is expected to be about US$ 135.97 Million by 2032
A distinctive feature of the newborn stage is the unbreakable bond between a mother and her child. The hospitalization of their infant or child, however, is one of the most painful events in a parent's life and can have a significant impact on their life. Hospitalization for phototherapy within the first few days of life might lead to issues such as nosocomial infections.
It is possible to recommend home phototherapy as a risk-free treatment option for patients with no side effects. As a result, it is boosting the global infant phototherapy device market. It is a more reasonable choice as well. The NIH stated that the average cost reductions per patient were €819 (95% confidence interval €613-1025) or 71% when comparing the cost per patient of home phototherapy to the hospital alternative, which was €1156.
The market for infant phototherapy is expanding as a result of novel ways to treat neonatal hyperbilirubinemia that have been made possible by technological advancements in phototherapy. A noteworthy research area is LED phototherapy, which has been the focus of studies assessing its effectiveness in treating unconjugated hyperbilirubinemia. Home phototherapy (HPT) devices at a low cost have been created to increase accessibility, especially in developing nations. A couple of examples include the Brilliance jaundice treatment device and the Iranian HPT system, which are intended to provide affordable options for phototherapy in homes.
These devices are designed to overcome gaps in healthcare access, especially in areas where implementing standard hospital-based phototherapy may be difficult. Another interesting advancement is the use of LED panels into a phototherapy system. Wearable phototherapy has being investigated by researchers as a cutting-edge strategy for driving innovation. Neonatal care is undergoing revolutionary changes through the adoption of varied methodologies, with the goal of improving treatment accessibility, efficacy, and patient experience.
The United States might have a considerable share in the global infant phototherapy device market. This is due to the prevalence of neonatal jaundice. A JAMA Network report states that between 60% and 70% of the 4 million babies born in the United States each year have clinical jaundice. The consumer awareness initiatives further propel the worldwide infant phototherapy device industry. For example, in 2023, the International Society for Neonatal Screening (ISNS) and the Association of Public Health Laboratories (APHL) joined forces to showcase global advancements and possibilities in neonatal screening.
The high rate of diagnosis and treatment and technological advancements further drive the infant phototherapy device market. For example, the FDA-approved "SkyLife" device, which is now under examination, is a mattress that uses blue LEDs as its light source, just like the existing blue LED panel devices. Because it produces safer, non-ultraviolet light, this gadget is thought to prevent many of the ill effects associated with using fluorescent tube lights. It is also more efficient than using mattresses or blankets, which rely on fluorescent tubes or blue halogen bulbs for lighting. The light is emitted under the infant.
No comments: